Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study

BACKGROUND: The choice between infliximab (IFX) and vedolizumab (VED) as a first-line biological agent in moderate-to-severe ulcerative colitis (UC) can be difficult. Second-line vedolizumab (VED) efficacy may decline following prior infliximab (IFX) treatment failure in UC patients. However, it is...

Descripción completa

Detalles Bibliográficos
Autores principales: Pudipeddi, Aviv, Ko, Yanna, Paramsothy, Sudarshan, Leong, Rupert W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908405/
https://www.ncbi.nlm.nih.gov/pubmed/35282607
http://dx.doi.org/10.1177/17562848221080793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908405/
https://www.ncbi.nlm.nih.gov/pubmed/35282607
http://dx.doi.org/10.1177/17562848221080793

Ejemplares similares